FDA Advisory Committee Unanimously Recommends First mRNA Flu Vaccine for Older Adults

In a landmark decision that could reshape seasonal respiratory protection, the Food and Drug Administration's top vaccine advisory committee has voted unanimously to recommend the first mRNA-based influenza vaccine for adults aged 50 and older.[1][2]

The 9-0 vote by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) on June 18 endorsed Moderna's investigational vaccine, known as mRNA-1010 or mFlusiva. The panel concluded that the shot's benefits decisively outweigh its risks, clearing a major hurdle toward a final approval decision expected by early August.[2][4]

If approved, the vaccine would mark the first time mRNA technology—which gained global prominence during the COVID-19 pandemic—has been successfully adapted for the seasonal flu, initiating a shift away from manufacturing methods that have dominated the industry for nearly 80 years.[1][6]

The primary advantage of the mRNA platform lies in its speed. Traditional influenza vaccines are predominantly grown in chicken eggs, a cumbersome process that requires a six-month lead time. This forces global health authorities to predict which flu strains will circulate half a year before the winter season begins.[4][6]

Because mRNA vaccines encode hemagglutinin proteins in lipid nanoparticles rather than relying on live virus cultivation, the manufacturing timeline is compressed to just two to three months. This rapid turnaround allows scientists to select target strains much closer to the actual flu season, significantly reducing the risk of a mismatch.[4][6]

Public health officials have long warned about "antigenic drift"—the process by which the flu virus mutates between the time a vaccine is designed and when it is administered. A faster production cycle not only mitigates this drift but also provides a critical infrastructure advantage if a novel pandemic flu strain were to suddenly emerge.[1][4]

The committee's unanimous endorsement was anchored by robust efficacy data from the FLUENT Phase 3 clinical trial, which evaluated the vaccine's performance during the severe 2024-2025 flu season.[3][5]

Published in the New England Journal of Medicine, the double-blind, active-controlled study enrolled over 40,700 participants aged 50 and older across 11 countries. Half received the experimental mRNA-1010 shot, while the other half received a licensed standard-dose comparator vaccine.[3][5]

The results demonstrated clear superiority. The mRNA vaccine achieved a relative vaccine efficacy of 26.6% against RT-PCR-confirmed influenza-like illness when compared directly to the standard-dose shot, meeting all primary efficacy endpoints.[2][3]

More importantly for health systems, the vaccine's protection against higher-level healthcare outcomes was even stronger. Efficacy against emergency room visits, hospitalizations, and urgent care use rose to 47.9%, suggesting the mRNA platform is particularly adept at preventing severe disease in older populations.[3][4]

However, the enhanced protection comes with a trade-off in reactogenicity. The safety profile of the flu shot closely mirrors the public's experience with mRNA COVID-19 vaccines, featuring higher rates of transient side effects than traditional flu shots.[1][6]

In the trial, 65.8% of mRNA recipients reported injection-site pain, 45.1% experienced fatigue, and 37.8% reported headaches. While the FDA panel noted these rates were higher than the comparator, they emphasized that the adverse events were predominantly mild-to-moderate and self-limiting, resolving within a few days.[3][4]

The path to the June VRBPAC vote was unusually turbulent. In February 2026, the FDA issued a rare "refusal-to-file" letter, initially declining to even review Moderna's application.[2][6]

The agency's initial objection centered on trial design. Regulators argued that Moderna should have tested its vaccine against a high-dose flu shot—the preferred standard of care for seniors—rather than a standard-dose comparator. Following intense public scrutiny and a formal meeting with the company, the FDA reversed its decision weeks later.[2][4]

To bridge the evidentiary gap for the oldest patients, the FDA and Moderna agreed to a bifurcated regulatory approach. The advisory panel voted to recommend standard approval for adults aged 50 to 64, but utilized an accelerated approval pathway for adults 65 and older.[2][4]

As a condition of this accelerated approval, Moderna is required to conduct a massive Phase 4 post-marketing study. This confirmatory trial is expected to enroll up to 800,000 participants across two flu seasons to definitively prove real-world effectiveness against high-dose comparators in the 65-and-older demographic.[4][5]

With the advisory committee's unanimous backing secured, the FDA is scheduled to make its final authorization decision by August 5, 2026. If approved, the first mRNA seasonal flu vaccine will be available in pharmacies and clinics for the upcoming fall respiratory season.[1][2]